12-gene molecular score endopredict (Myriad Genetics)
90
Structured Review
Myriad Genetics
12-gene molecular score endopredict
12 Gene Molecular Score Endopredict, supplied by Myriad Genetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/12-gene+molecular+score+endopredict/12+gene+risk+score+endopredict/pm30663337-18-61-66
Average 90 stars, based on 1 article reviews
12 Gene Molecular Score Endopredict, supplied by Myriad Genetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/12-gene+molecular+score+endopredict/12+gene+risk+score+endopredict/pm30663337-18-61-66
Average 90 stars, based on 1 article reviews
12-gene molecular score endopredict - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Adjuvant:Article Title: Multi-gene assays: effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer. Article Snippet: The most recent (2018) NCCN Guidelines R© recognize several MGAs for consideration of adjuvant systemic chemotherapy, including the 21-gene Recurrence Score R© test (Oncotype DX Breast Recurrence Score R©, Genomic Health, Inc., CA, USA), the 70-gene signature using microarray technology (MammaPrint R©, Agendia, CA, USA), the commercial PAM50 risk of recurrence (ROR; Prosigna R©, NanoString Technologies, Inc., WA, USA) and the Microarray:Article Title: Multi-gene assays: effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer. Article Snippet: The most recent (2018) NCCN Guidelines R© recognize several MGAs for consideration of adjuvant systemic chemotherapy, including the 21-gene Recurrence Score R© test (Oncotype DX Breast Recurrence Score R©, Genomic Health, Inc., CA, USA), the 70-gene signature using microarray technology (MammaPrint R©, Agendia, CA, USA), the commercial PAM50 risk of recurrence (ROR; Prosigna R©, NanoString Technologies, Inc., WA, USA) and the |